PMID- 17278094
OWN - NLM
STAT- MEDLINE
DCOM- 20070417
LR  - 20161124
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 120
IP  - 9
DP  - 2007 May 1
TI  - The effects of combined antioxidant (beta-carotene, alpha-tocopherol and ascorbic 
      acid) supplementation on antioxidant capacity, DNA single-strand breaks and 
      levels of insulin-like growth factor-1/IGF-binding protein 3 in the ferret model 
      of lung cancer.
PG  - 1847-54
AB  - Insulin-like growth factor 1 (IGF-1) and its major binding protein, IGF binding 
      protein 3 (IGFBP-3) are implicated in lung cancer and other malignancies. We have 
      previously shown that the combination of three major antioxidants [beta-carotene 
      (BC), alpha-tocopherol (AT) and ascorbic acid (AA)] can prevent lung 
      carcinogenesis in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-treated 
      and smoke-exposed (SM) ferret model, which is highly analogous to humans. The 
      present study is aimed at determining the effect of the combination of BC, AT and 
      AA on antioxidant capacity, lymphocyte DNA damage, plasma IGF-1 and IGFBP-3 
      concentrations, as well as on IGF-1/IGFBP-3 mRNA expression in the tissues (lung 
      and liver) of the ferrets. Ferrets were treated with or without combined 
      antioxidant (BC, AT and AA) supplementation (AOX) for 6 months in the following 4 
      groups: (i) control; (ii) SM+NNK; (iii) AOX; and (iv) SM+NNK+AOX. Combined AOX 
      supplementation significantly attenuated SM+NNK induced lymphocyte DNA damage in 
      the ferret, while increasing resistance to oxidative damage when challenged with 
      H(2)O(2) in vitro. Ferrets treated with SM+NNK had significantly lower IGFBP-3 
      mRNA expression in lungs, whereas there was significantly higher IGFBP-3 mRNA 
      expression in the liver, as well as higher circulating IGFBP-3 concentrations. 
      Combined AOX supplementation did not affect the plasma or tissue (lung and liver) 
      ratio of IGF-1/IGFBP-3. Combined antioxidant supplementation provides protection 
      against smoke-induced oxidative DNA damage, but does not affect the IGF-1/IGFBP-3 
      system. Differential expression of IGFBP-3 in different tissues indicates that 
      caution should be taken when using plasma IGFBP-3 as a biomarker of tissue 
      status.
CI  - (c) 2007 Wiley-Liss, Inc.
FAU - Kim, Yuri
AU  - Kim Y
AD  - Jean Mayer United States Department of Agriculture Human Nutrition Research 
      Center on Aging, Tufts University, Boston, MA, USA.
FAU - Lian, Fuzhi
AU  - Lian F
FAU - Yeum, Kyung-Jin
AU  - Yeum KJ
FAU - Chongviriyaphan, Nalinee
AU  - Chongviriyaphan N
FAU - Choi, Sang-Woon
AU  - Choi SW
FAU - Russell, Robert M
AU  - Russell RM
FAU - Wang, Xiang-Dong
AU  - Wang XD
LA  - eng
GR  - T32 DK062032/DK/NIDDK NIH HHS/United States
GR  - R01CA104932/CA/NCI NIH HHS/United States
GR  - R01CA49195/CA/NCI NIH HHS/United States
GR  - T32 DK62032/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antioxidants)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 0 (Nitrosamines)
RN  - 0 (Smoke)
RN  - 01YAE03M7J (beta Carotene)
RN  - 1406-18-4 (Vitamin E)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 7S395EDO61 (4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone)
RN  - PQ6CK8PD0R (Ascorbic Acid)
SB  - IM
MH  - Animals
MH  - Antioxidants/*administration & dosage/analysis
MH  - Ascorbic Acid/administration & dosage
MH  - *DNA Breaks, Single-Stranded
MH  - Disease Models, Animal
MH  - Ferrets
MH  - Insulin-Like Growth Factor Binding Protein 3/*analysis/genetics
MH  - Insulin-Like Growth Factor I/*analysis/genetics
MH  - Liver/metabolism
MH  - Lung/metabolism
MH  - Lung Neoplasms/*drug therapy/genetics/metabolism
MH  - Male
MH  - Nitrosamines/toxicity
MH  - Smoke/adverse effects
MH  - Vitamin E/administration & dosage
MH  - beta Carotene/administration & dosage
EDAT- 2007/02/06 09:00
MHDA- 2007/04/18 09:00
CRDT- 2007/02/06 09:00
PHST- 2007/02/06 09:00 [pubmed]
PHST- 2007/04/18 09:00 [medline]
PHST- 2007/02/06 09:00 [entrez]
AID - 10.1002/ijc.22320 [doi]
PST - ppublish
SO  - Int J Cancer. 2007 May 1;120(9):1847-54. doi: 10.1002/ijc.22320.